Skip to content

Main Navigation

Super Critical Carbon Dioxide in the Large Scale Drug Manufacturing


There is an urgent need for the development of novel large-scale manufacture engineering methods, which enhance sustainability and renewability while minimizing or eliminating the use of hazardous chemicals, biologicals and solvents that are harmful to the earth. In this regard, use of supercritical carbon dioxide (scCO2) solvent is very attractive as scCO2 is easily available, non-toxic, non-flammable, and amenable for large-scale reactions. Furthermore, its properties can easily be tuned through changing temperature and pressure. We propose to exploit the advantages of scCO2 in the development of novel manufacturing processes for the production of biotechnological heparin anticoagulants. Currently heparin anticoagulants are derived from over 700 million pigs and used in over 100 million surgical procedures annually worldwide and listed as one of the most critical essential medicines by World Health Organization. In addition, continuous availability of heparin blood thinner is at risk due to recent spread of African Swine Fever in China and elsewhere. Finally, we also explore the use of scCO2 in the continuous manufacturing of advanced pharmaceutical ingredients that have limited water solubility.

The team has faculty members from Medicinal Chemistry, Hunstman Cancer Institute [University of Utah Therapeutics Accelerator Hub (U2-TAH)] and Chemical Engineering with expertise in the chemistry of drugs being manufactured and in supercritical extraction.

Collaborators

KUBERAN BALAGURUNATHAN
College of Pharmacy
Medicinal Chemistry
Project Owner

MILIND DEO
College of Engineering
Chemical Engineering

HARIPRASAD VANKAYALAPATI
College of Pharmacy
Medicinal Chemistry

Project Info

Funded Project Amount
$30K

Keywords
super critical carbon dioxide, green chemistry, sustainability, drug manufacturing, drug formulation, heparin, blood thinner

Project Status
Funded 2020
Last Updated: 1/23/20